Clinical Trials
3 trialsNCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT02988726 2017-07-26
Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma
Burzynski Research Institute
Phase 2 Terminated
NCT00973739 2016-03-22
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NYU Langone Health
Phase 2 Completed